Despite being seen as innovation hubs, universities face identical organizational barriers as large corporations. Academics report that internal power structures, cultural inertia, and siloed departments create bottlenecks that prevent them from effectively commercializing novel IP, mirroring corporate struggles.

Scientists exist in a state of economic precarity, unable to risk their careers by pursuing heterodox ideas. Without the security and prosperity afforded to other fields, they are forced to conform to established narratives to gain tenure, funding, and basic financial stability, stifling breakthrough innovation.

Corporate creativity follows a bell curve. Early-stage companies and those facing catastrophic failure (the tails) are forced to innovate. Most established companies exist in the middle, where repeating proven playbooks and playing it safe stifles true risk-taking.

While processes are essential for scaling, excessive rigidity stifles the iterative and experimental nature of innovation. Organizations must balance operational efficiency with the flexibility needed for creative breakthroughs, as too much process kills new ideas.

The 'Matthew effect' entrenches established scientists who can stifle new ideas. Economist Pierre Azoulay's research confirms that publications and citations from a lab often increase after the lead scientist dies, as their departure allows new perspectives to flourish.

The biotech industry is uniquely conservative, with a culture where even the smartest minds are beholden to established processes. This resistance to questioning norms, like automatically running two Phase 3 trials, stifles innovation and slows progress compared to other technology sectors.

Large institutions, even those designed to foster innovation, are fundamentally conservative. Their investments in real estate, careers, and the status quo make them inherently resistant to the revolutionary change that defines major breakthroughs.

Disruptive ideas within large companies trigger an organizational "immune system response." Just as biological antibodies attack foreign invaders, the corporate structure, designed for predictability, attacks novel ideas, preventing radical innovation from taking root.

Established companies operate an 'execution engine' that values predictability and eliminates failure. This directly conflicts with the 'innovation engine,' which requires uncertainty, experimentation, and learning from failure to discover future value. This fundamental tension is the primary reason corporate innovation initiatives often stall or fail.